TLX News: Telix Submits NDA for New Prostate Cancer Imaging Agent - 28th May 2024, 9:00pm

annb0t

Top 20
Telix Pharmaceuticals Limited

MELBOURNE, Australia, May 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”) for the preparation of PSMA-PET imaging1 for prostate cancer.

Subject to regulatory approval, this Kit will enable use of a PSMA imaging product with a considerab...

>>> Read more: Telix Submits NDA for New Prostate Cancer Imaging Agent
 
Top Bottom